出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2017/12/16 21:05:58」(JST)
この項目では、試料の分析法である「ELISA」について説明しています。
|
この記事は検証可能な参考文献や出典が全く示されていないか、不十分です。 出典を追加して記事の信頼性向上にご協力ください。(2017年4月) |
ELISA (Enzyme-Linked ImmunoSorbent Assay) は、試料中に含まれる抗体あるいは抗原の濃度を検出・定量する際に用いられる方法。「酵素結合免疫吸着法」などの訳語があるが定訳はなく、一般に、エライサあるいはエライザと呼ばれる。
生体試料中には、種々雑多なタンパク質が存在するが、特定のタンパク質を検出・定量するには、特に他のタンパク質と比べて微量にしか存在しない場合は、特異性の高さ(夾雑物からどれだけ正確に区別できるか)と定量性の良さ(微量であっても検出できる、あるいは低濃度における再現性の良さ)が求められる。ELISAは特異性の高い抗原抗体反応を利用し、酵素反応に基づく発色・発光をシグナルに用いることで上記の条件をクリアしている。ELISAは、同様の原理に基づく放射免疫測定(ラジオイムノアッセイ、RIA)と比べて、放射性物質を用いないため安全性が高く、安価で簡便であるため、現在微量タンパク質や感染微生物抗原の検出・定量に広く用いられている。
以下に、タンパク質を定量する際に用いられる方法のうち代表的な物を記載する。いずれの方法においても、検量線を作成し、そこから定量する方法が一般的である。
この方法は簡便であるが、最初のステップにおいて目的タンパク質以外のタンパク質が多量に存在する場合は、それらのタンパク質の影響を受けてしまうため、定量性が悪くなる。また、タンパク質によっては微量な領域での吸着が定量的でなくなるなど、タンパク質の量および性質により定量性が悪くなる欠点を持っている。
本方法を行うには、同一タンパク質を異なるエピトープで認識する抗体が必要となる。また、抗体の立体障害を考えると、近位ではなく遠位(アミノ酸配列上でなく立体構造上の遠位)を認識することが望ましい。最大の利点は、同一タンパク質を捕獲抗体と一次抗体の2種類の抗体を用いて検出する性質上、特異性が非常に高い方法である。ただし、固相に吸着させる捕獲抗体の量が少ない場合、試料中の抗原は捕獲抗体以上の量が結合できないため、定量性が悪くなることがある。
この方法は、直接吸着法における微量タンパク質の定量性の低さを改善し、抗原に対して一種類の抗体で高感度に検出できる方法である。ただし、直接結合法と同様に用いる抗体によっては、交差反応により十分な特異性が得られないときがある。このような場合には何らかの前処理が必要となる。
この項目は、医学に関連した書きかけの項目です。この項目を加筆・訂正などしてくださる協力者を求めています(プロジェクト:医学/Portal:医学と医療)。 |
ELISA | |
---|---|
A 96-well microtiter plate being used for ELISA
|
|
MeSH | D004797 |
[edit on Wikidata]
|
The enzyme-linked immunosorbent assay (ELISA) (/ɪˈlaɪzə/, /ˌiːˈlaɪzə/) is a test that uses antibodies and color change to identify a substance.
ELISA is a popular format of "wet-lab" type analytic biochemistry assay that uses a solid-phase enzyme immunoassay (EIA) to detect the presence of a substance, usually an antigen, in a liquid sample or wet sample.
The ELISA has been used as a diagnostic tool in medicine and plant pathology, as well as a quality-control check in various industries.
Antigens from the sample are attached to a surface. Then, a further specific antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and, in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate.
Performing an ELISA involves at least one antibody with specificity for a particular antigen. The sample with an unknown amount of antigen is immobilized on a solid support (usually a polystyrene microtiter plate) either non-specifically (via adsorption to the surface) or specifically (via capture by another antibody specific to the same antigen, in a "sandwich" ELISA). After the antigen is immobilized, the detection antibody is added, forming a complex with the antigen. The detection antibody can be covalently linked to an enzyme, or can itself be detected by a secondary antibody that is linked to an enzyme through bioconjugation. Between each step, the plate is typically washed with a mild detergent solution to remove any proteins or antibodies that are non-specifically bound. After the final wash step, the plate is developed by adding an enzymatic substrate to produce a visible signal, which indicates the quantity of antigen in the sample.
Of note, ELISA can perform other forms of ligand binding assays instead of strictly "immuno" assays, though the name carried the original "immuno" because of the common use and history of development of this method. The technique essentially requires any ligating reagent that can be immobilized on the solid phase along with a detection reagent that will bind specifically and use an enzyme to generate a signal that can be properly quantified. In between the washes, only the ligand and its specific binding counterparts remain specifically bound or "immunosorbed" by antigen-antibody interactions to the solid phase, while the nonspecific or unbound components are washed away. Unlike other spectrophotometric wet lab assay formats where the same reaction well (e.g. a cuvette) can be reused after washing, the ELISA plates have the reaction products immunosorbed on the solid phase which is part of the plate, and so are not easily reusable.
As an analytic biochemistry assay, ELISA involves detection of an "analyte" (i.e. the specific substance whose presence is being quantitatively or qualitatively analyzed) in a liquid sample by a method that continues to use liquid reagents during the "analysis" (i.e. controlled sequence of biochemical reactions that will generate a signal which can be easily quantified and interpreted as a measure of the amount of analyte in the sample) that stays liquid and remains inside a reaction chamber or well needed to keep the reactants contained; It is opposed to "dry lab" that can use dry strips – and even if the sample is liquid (e.g. a measured small drop), the final detection step in "dry" analysis involves reading of a dried strip by methods such as reflectometry and does not need a reaction containment chamber to prevent spillover or mixing between samples.
As a heterogenous assay, ELISA separates some component of the analytical reaction mixture by adsorbing certain components onto a solid phase which is physically immobilized. In ELISA, a liquid sample is added onto a stationary solid phase with special binding properties and is followed by multiple liquid reagents that are sequentially added, incubated and washed followed by some optical change (e.g. color development by the product of an enzymatic reaction) in the final liquid in the well from which the quantity of the analyte is measured. The qualitative "reading" usually based on detection of intensity of transmitted light by spectrophotometry, which involves quantitation of transmission of some specific wavelength of light through the liquid (as well as the transparent bottom of the well in the multiple-well plate format). The sensitivity of detection depends on amplification of the signal during the analytic reactions. Since enzyme reactions are very well known amplification processes, the signal is generated by enzymes which are linked to the detection reagents in fixed proportions to allow accurate quantification – thus the name "enzyme linked".
The analyte is also called the ligand because it will specifically bind or ligate to a detection reagent, thus ELISA falls under the bigger category of ligand binding assays. The ligand-specific binding reagent is "immobilized", i.e., usually coated and dried onto the transparent bottom and sometimes also side wall of a well (the stationary "solid phase'/"solid substrate" here as opposed to solid microparticle/beads that can be washed away), which is usually constructed as a multiple-well plate known as the "ELISA plate". Conventionally, like other forms of immunoassays, the specificity of antigen-antibody type reaction is used because it is easy to raise an antibody specifically against an antigen in bulk as a reagent. Alternatively, if the analyte itself is an antibody, its target antigen can be used as the binding reagent.
Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a scientific paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960.[1]
Because radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a nonradioactive signal in place of the radioactive signal. When enzymes (such as horseradish peroxidase) react with appropriate substrates (such as ABTS or TMB), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G. B. Pierce.[2] Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent must be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966.[3]
In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in the Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.[4][5]
Traditional ELISA typically involves chromogenic reporters and substrates that produce some kind of observable color change to indicate the presence of antigen or analyte. Newer ELISA-like techniques use fluorogenic, electrochemiluminescent, and quantitative PCR reporters to create quantifiable signals. These new reporters can have various advantages, including higher sensitivities and multiplexing.[6][7] In technical terms, newer assays of this type are not strictly ELISAs, as they are not "enzyme-linked", but are instead linked to some nonenzymatic reporter. However, given that the general principles in these assays are largely similar, they are often grouped in the same category as ELISAs.
In 2012, an ultrasensitive, enzyme-based ELISA test using nanoparticles as a chromogenic reporter was able to give a naked-eye colour signal, from the detection of mere attograms of analyte. A blue color appears for positive results and red color for negative. Note that this detection only can confirm the presence or the absence of analyte not the actual concentration.[8]
The steps of direct ELISA follows the mechanism below:
The enzyme acts as an amplifier; even if only few enzyme-linked antibodies remain bound, the enzyme molecules will produce many signal molecules. Within common-sense limitations, the enzyme can go on producing color indefinitely, but the more antibody is bound, the faster the color will develop. A major disadvantage of the direct ELISA is the method of antigen immobilization is not specific; when serum is used as the source of test antigen, all proteins in the sample may stick to the microtiter plate well, so small concentrations of analyte in serum must compete with other serum proteins when binding to the well surface. The sandwich or indirect ELISA provides a solution to this problem, by using a "capture" antibody specific for the test antigen to pull it out of the serum's molecular mixture.
ELISA may be run in a qualitative or quantitative format. Qualitative results provide a simple positive or negative result (yes or no) for a sample. The cutoff between positive and negative is determined by the analyst and may be statistical. Two or three times the standard deviation (error inherent in a test) is often used to distinguish positive from negative samples. In quantitative ELISA, the optical density (OD) of the sample is compared to a standard curve, which is typically a serial dilution of a known-concentration solution of the target molecule. For example, if a test sample returns an OD of 1.0, the point on the standard curve that gave OD = 1.0 must be of the same analyte concentration as the sample.
The use and meaning of the names "direct ELISA" and "indirect ELISA" differs in the literature and on web sites depending on the context of the experiment. When the presence of an antigen is analyzed, the name "direct ELISA" refers to an ELISA in which only a labelled primary antibody is used, and the term "indirect ELISA" refers to an ELISA in which the antigen is bound by the primary antibody which then is detected by a labeled secondary antibody. In the latter case a sandwich ELISA is clearly distinct from an indirect ELISA. When the "primary" antibody is of interest, e.g. in the case of immunization analyses, this antibody is directly detected by the secondary antibody and the term "indirect ELISA" applies to a setting with two antibodies.
A "sandwich" ELISA is used to detect sample antigen.[9] The steps are:
The image to the right includes the use of a secondary antibody conjugated to an enzyme, though, in the technical sense, this is not necessary if the primary antibody is conjugated to an enzyme (which would be direct ELISA). However, the use of a secondary-antibody conjugate avoids the expensive process of creating enzyme-linked antibodies for every antigen one might want to detect. By using an enzyme-linked antibody that binds the Fc region of other antibodies, this same enzyme-linked antibody can be used in a variety of situations. Without the first layer of "capture" antibody, any proteins in the sample (including serum proteins) may competitively adsorb to the plate surface, lowering the quantity of antigen immobilized. Use of the purified specific antibody to attach the antigen to the plastic eliminates a need to purify the antigen from complicated mixtures before the measurement, simplifying the assay, and increasing the specificity and the sensitivity of the assay. A sandwich ELISA used for research often need validation because of the risk of false positive results.[10]
A third use of ELISA is through competitive binding. The steps for this ELISA are somewhat different from the first two examples:
Some competitive ELISA kits include enzyme-linked antigen rather than enzyme-linked antibody. The labeled antigen competes for primary antibody binding sites with the sample antigen (unlabeled). The less antigen in the sample, the more labeled antigen is retained in the well and the stronger the signal.
Commonly, the antigen is not first positioned in the well.
For the detection of HIV antibodies, the wells of microtiter plate are coated with the HIV antigen. Two specific antibodies are used, one conjugated with enzyme and the other present in serum (if serum is positive for the antibody). Cumulative competition occurs between the two antibodies for the same antigen, causing a stronger signal to be seen. Sera to be tested are added to these wells and incubated at 37 °C, and then washed. If antibodies are present, the antigen-antibody reaction occurs. No antigen is left for the enzyme-labelled specific HIV antibodies. These antibodies remain free upon addition and are washed off during washing. Substrate is added, but there is no enzyme to act on it, so a positive result shows no color change.
Because the ELISA can be performed to evaluate either the presence of antigen or the presence of antibody in a sample, it is a useful tool for determining serum antibody concentrations (such as with the HIV test[11] or West Nile virus). It has also found applications in the food industry in detecting potential food allergens, such as milk, peanuts, walnuts, almonds, and eggs[12] and as serological blood test for coeliac disease.[13][14] ELISA can also be used in toxicology as a rapid presumptive screen for certain classes of drugs.
The ELISA was the first screening test widely used for HIV because of its high sensitivity. In an ELISA, a person's serum is diluted 400 times and applied to a plate to which HIV antigens are attached. If antibodies to HIV are present in the serum, they may bind to these HIV antigens. The plate is then washed to remove all other components of the serum. A specially prepared "secondary antibody" — an antibody that binds to other antibodies — is then applied to the plate, followed by another wash. This secondary antibody is chemically linked in advance to an enzyme.
Thus, the plate will contain enzyme in proportion to the amount of secondary antibody bound to the plate. A substrate for the enzyme is applied, and catalysis by the enzyme leads to a change in color or fluorescence. ELISA results are reported as a number; the most controversial aspect of this test is determining the "cut-off" point between a positive and a negative result.
A cut-off point may be determined by comparing it with a known standard. If an ELISA test is used for drug screening at workplace, a cut-off concentration, 50 ng/ml, for example, is established, and a sample containing the standard concentration of analyte will be prepared. Unknowns that generate a stronger signal than the known sample are "positive." Those that generate weaker signal are "negative".
Dr Dennis E Bidwell and Alister Voller created the ELISA test to detect various kind of diseases, such as malaria, Chagas disease, and Johne's disease.[15] ELISA tests also are used as in in vitro diagnostics in medical laboratories. The other uses of ELISA include:
Medical tests: Immunologic techniques and tests (CPT 86000–86849)
|
|||||||||
---|---|---|---|---|---|---|---|---|---|
Immunologic techniques and tests
|
|
||||||||
Inflammation |
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
リンク元 | 「類天疱瘡」「新生児マススクリーニング」「酵素結合免疫測定法」「enzyme-linked immunoassay」「酵素結合免疫吸着検定法」 |
拡張検索 | 「サンドイッチELISA法」 |
尋常性天疱瘡 | 落葉性天疱瘡 | 水疱性類天疱瘡 | ||
年齢 | 中年~老年 | 中年 | 老年(若年もあり) | |
好発部位 | 口腔粘膜、全身 | 全身 | 全身 | |
臨床像 | 皮膚所見 | 水疱、びらん | びらん、葉状落屑、 | 緊満性水疱、浮腫性紅斑、掻痒 |
粘膜浸潤 | ++ | 痂皮 | + | |
Nikolsky現象 | + | - | ||
病理組織像 | 所見 | 表皮内水疱 (棘融解) |
表皮下水疱 好酸球の浸潤 | |
Tzanck試験 | + | + | ||
棘融解部位 | 表皮下層(基底細胞直上) | 表皮上層(顆粒層) | ||
抗原 | Dsg3 のみ、 Dsg3 と1 の共存 |
Dsg1 のみ | BP180、BP230 | |
ELISA | Dsg1(+または-)、Dsg3(+) | Dsg1(+)、Dsg3(-) | ||
蛍光抗体法所見 | 直接法(病変部皮膚) | 表皮細胞間に IgG、C3 陽性 |
病変部基底膜部に IgG とC3 の線状沈着 | |
間接法(血清中) | 抗表皮細胞間物質抗体(IgG)陽性 | 抗基底膜抗体の検出 | ||
治療 | ステロイド、免疫抑制薬、血漿交換療法、γ グロブリン療法 | ステロイド内服、免疫抑制薬、DDSなど |
多い順 | 疾患名 | 検査法 | 測定物質 | 発見率 | 症状 | 治療法 | |
4 | フェニルケトン尿症 | Guthrie法 | フェニルアラニン | 1/80,000 | 知能障害、痙攣、メラニン欠乏 | 低フェニルアラニン食 | |
6 | メープルシロップ尿症 | ロイシン | 1/450,000 | 痙攣、意識障害、昏睡、知能障害 | 急性期治療、食事療法(分枝鎖アミノ酸制限) | ||
5 | ホモシスチン尿症 | メチオニン | 1/180,000 | 高身長、水晶体偏位、血栓症、知能障害 | ビタミンB6、低メチオニン高システイン食療法 | ||
3 | ガラクトース血症 | Beutler法./ Paigen法 |
gal-4-P トランスフェラーゼ/ ガラクトース |
1/40,000 | I型 | 肝障害、発育障害、白内障、知能障害 | |
II型 | 白内障 | 乳糖除去ミルク・除去食 | |||||
III型 | 大部分は末梢型で無症状 | ||||||
2 | 先天性副腎過形成症 | RIA法 ELISA |
17-OHプロゲステロン | 1/13,000 | 塩喪失症候群(ショック、脱水)、男性化徴候、色素沈着 | コルチゾール、フロリネフ | |
1 | 先天性甲状腺機能低下症 (クレチン症) |
TSH | 1/4,800 | 精神発達遅滞、発育遅延、巨舌、黄疸の遷延、臍ヘルニア | 甲状腺ホルモン補充療法 |
.